Bone regeneration with recombinant human bone morphogenetic protein 2: a systematic review

Fernandes, Jannice de Queiroz; Lima, Valthierre Nunes de; Bonardi, João Paulo; Magro‐Filho, Osvaldo; Queiroz, Sormani Bento Fernandes de

doi:10.1007/s12663-016-0988-1

Cited by 24 publications

(17 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For MTF coated with hrBMP‐2, with or without gentamicin, the differentiation was more than double the differentiation on bare MTFs. This result was expected as the effectiveness of hrBMP‐2 in promoting preosteoblast differentiation has been demonstrated in a large number of works …”

Section: Resultsmentioning

confidence: 87%

Antibacterial Mesoporous Titania Films with Embedded Gentamicin and Surface Modified with Bone Morphogenetic Protein 2 to Promote Osseointegration in Bone Implants

Escobar

Muzzio

Coy

et al. 2019

Adv Materials Inter

View full text Add to dashboard Cite

Novel approaches are needed to avoid bacterial infections following implant surgery. Here the use of mesoporous titania films (MTFs) for gentamicin loading and delivery and the surface functionalization of MFTs with human recombinant bone morphogenetic protein 2 (hrBMP‐2) are discussed. Gentamicin is incorporated into the MTF pores by immersion of the porous materials in gentamicin solution while hrBMP‐2 is adsorbed on top of the MTF. Contact angle and X‐ray photoelectron spectroscopy measurements are performed to prove gentamicin loading and hrBMP‐2 functionalization. An initial burst release of gentamicin takes place in physiological media followed by a prolonged release that lasts weeks. Such a release profile is highly appealing for bone implants where a high concentration of antibiotics is necessary during implant surgery while a lower antibiotic concentration is needed until tissue is regenerated. The MTFs loaded with gentamicin and functionalized with hrBMP‐2 are effective against Staphylococcus aureus colonization, and the presence of hrBMP‐2 enhances MC3T3‐E1 preosteoblastic cell attachment, proliferation, and differentiation.

show abstract

Section: Resultsmentioning

confidence: 87%

Antibacterial Mesoporous Titania Films with Embedded Gentamicin and Surface Modified with Bone Morphogenetic Protein 2 to Promote Osseointegration in Bone Implants

Escobar

Muzzio

Coy

et al. 2019

Adv Materials Inter

View full text Add to dashboard Cite

show abstract

“…In light of these considerations, the actual tendency is to prefer minimally-invasive-surgical procedures and to look for highly performant materials to limit the use of synthetic membranes, especially when treating contentive defects. Even though these regenerative materials are still used today, the introduction of biomimetic agents, such as enamel matrix derivatives, bone morphogenetic proteins, and platelets concentrates, raises new opportunities for better outcomes in periodontal treatment [ 4 , 5 , 6 , 7 ]. In very recent years, also the topical application of hyaluronic acid has further expanded the whole panorama of performant regenerative materials thanks to its favorable benefits in clinical attachment level (CAL) gain and vertical pocket probing depth (PPD) reduction when applied both in non-surgical and surgical periodontal therapy [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Use of Platelet-Rich Fibrin in the Treatment of Grade 2 Furcation Defects: Systematic Review and Meta-Analysis

Tarallo

Mancini

Pitzurra

et al. 2020

JCM

View full text Add to dashboard Cite

In periodontitis patients, furcation defects are crucial sites to regenerate due to their complex anatomy. Various modern surgical techniques and use of biomaterials have been suggested in the literature. Among all, platelet-rich fibrin (PRF) has potential in tissue regeneration thanks to its role in the release of growth factors. Therefore, the purpose of this study was to evaluate the beneficial effect of the addition of PRF to open flap debridement (OFD) or as an adjuvant to other biomaterials such as bone grafts in the treatment of grade 2 mandibular furcation defects. Systematic research was carried out on the databases Medline, Scopus, Embase, and Cochrane Library and registered on PROSPERO (CRD42020167662). According to the PICO guidelines by Cochrane, randomized trials and prospective non-randomized trials were evaluated, with a minimum follow-up period of 6 months. The inclusion criteria were the absence of systemic diseases, non-smoking patients, and a population aged from 18 to 65 years. Vertical pocket probing depth (PPD), vertical clinical attachment level (VCAL), and gingival recession (REC) were the primary outcomes. Vertical furcation depth (VFD), and the percentage of bone defect fill (%v-BDF) were considered as secondary outcomes. A meta-analysis of the primary and secondary outcomes was performed. Publication bias was assessed through a funnel plot. Eighty-four articles were initially extracted. Eight randomized clinical trials were analyzed according to the exclusion and inclusion criteria. The Quality assessment instrument (QAI) revealed four articles at low risk of bias, one at moderate, and three at high risk of bias. The metanalysis showed significant data regarding PPD, VCAL, VFD and %v-BDF in the comparison between PRF + OFD vs. OFD alone. The adjunct of PRF to a bone graft showed a significant difference for VCAL and a not statistically significant result for the other involved parameters. In conclusion, the adjunctive use of PRF to OFD seems to enhance the periodontal regeneration in the treatment of grade 2 furcation defects. The combination of PRF and bone graft did not show better clinical results, except for VCAL, although the amount of literature with low risk of bias is scarce. Further well-designed studies to evaluate the combination of these two materials are therefore needed.

show abstract

“…Consequently, there are efforts to develop preparations, such as platelet‐rich plasma (PRP) gels or PRP combined with other biological materials such as demineralized bone matrix or cells, to extend the biological activity of PRP . PRP has been used in a number of clinical settings for bone regeneration cartilage repair, treatment of osteoarthritis, and tendon/ligament and meniscal repair . However, the biological action of PRP, eg, in regulating differentiation of multipotent MSCs, remains unclear.…”

Section: Key Question 2: What Is the Current Knowledge About The Thermentioning

confidence: 99%

American Society for Bone and Mineral Research‐Orthopaedic Research Society Joint Task Force Report on Cell‐Based Therapies – Secondary Publication

O’Keefe

Tuan

Lane

et al. 2020

Journal Orthopaedic Research

View full text Add to dashboard Cite

Cell‐based therapies, defined here as the delivery of cells in vivo to treat disease, have recently gained increasing public attention as a potentially promising approach to restore structure and function to musculoskeletal tissues. Although cell‐based therapy has the potential to improve the treatment of disorders of the musculoskeletal system, there is also the possibility of misuse and misrepresentation of the efficacy of such treatments. The medical literature contains anecdotal reports and research studies, along with web‐based marketing and patient testimonials supporting cell‐based therapy. Both the American Society for Bone and Mineral Research (ASBMR) and the Orthopaedic Research Society (ORS) are committed to ensuring that the potential of cell‐based therapies is realized through rigorous, reproducible, and clinically meaningful scientific discovery. The two organizations convened a multidisciplinary and international Task Force composed of physicians, surgeons, and scientists who are recognized experts in the development and use of cell‐based therapies. The Task Force was charged with defining the state‐of‐the art in cell‐based therapies and identifying the gaps in knowledge and methodologies that should guide the research agenda. The efforts of this Task Force are designed to provide researchers and clinicians with a better understanding of the current state of the science and research needed to advance the study and use of cell‐based therapies for skeletal tissues. The design and implementation of rigorous, thorough protocols will be critical to leveraging these innovative treatments and optimizing clinical and functional patient outcomes. In addition to providing specific recommendations and ethical considerations for preclinical and clinical investigations, this report concludes with an outline to address knowledge gaps in how to determine the cell autonomous and nonautonomous effects of a donor population used for bone regeneration. © 2020 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 38:485–502, 2020

show abstract

Bone regeneration with recombinant human bone morphogenetic protein 2: a systematic review

Abstract: It was concluded that the treatment with rhBMP-2 foi satisfactory in most cases and the placement of dental implants in the bone regenerated with rhBMP-2 is feasible.

Cited by 24 publications

References 23 publications

Antibacterial Mesoporous Titania Films with Embedded Gentamicin and Surface Modified with Bone Morphogenetic Protein 2 to Promote Osseointegration in Bone Implants

Antibacterial Mesoporous Titania Films with Embedded Gentamicin and Surface Modified with Bone Morphogenetic Protein 2 to Promote Osseointegration in Bone Implants

Use of Platelet-Rich Fibrin in the Treatment of Grade 2 Furcation Defects: Systematic Review and Meta-Analysis

American Society for Bone and Mineral Research‐Orthopaedic Research Society Joint Task Force Report on Cell‐Based Therapies – Secondary Publication

Contact Info

Product

Resources

About